 <!-- Fragment 05-->
<tr>
    <td width="550" style="padding-left: 15px; padding-right: 22px;padding-top: 35px;color: #005678;font-size: 18px;background:#ffffff;font-family: Arial, HelveticaNeue, Helvetica, sans-serif">
            <table width="550" align="left" border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, HelveticaNeue, Helvetica, sans-serif; background-color: #ffffff;margin-top:12px;border-bottom:1px solid #e5e5e5;padding-bottom:30px;border-collapse: collapse">  
<tr>
	<td>
            <table width="550" align="left" border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, HelveticaNeue, Helvetica, sans-serif; background-color: #ffffff;margin-top:12px;margin-left:15px">  
                <tr>
                    <td style="color:#faa21b;font-size:26px;font-weight:bold;text-align: right;width:350px;padding: 16px 20px;line-height: 1.2;background: #005678" width="350">
                        CMS APPROVES <br>NTAP FOR BLINCYTO<br />
                        <em style="color:#ffffff;font-size:14px">Effective October 1, 2015</em>
                    </td>
                    <td width="150" style="background: #ffffff;">&nbsp;</td>
                </tr>
            </table>
	</td>
</tr>   
                <tr>
                	<td style="padding-left:20px">
                		 <table width="500" align="left" border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, HelveticaNeue, Helvetica, sans-serif; background-color: #ffffff;margin-top:12px;font-size: 18px;color:#005678">  
                    <tr>
                        <td style="color:#faa21b; vertical-align: top;padding:0">&#x25cf;</td>
                        <td style="line-height: 1.333;padding-left:10px;padding-bottom:20px">New Technology Add-on Payment (NTAP) is an additional payment for qualifying Medicare hospital inpatient cases</td>
                    </tr>
                    <tr>
                        <td style="color:#faa21b; vertical-align: top;padding:0">&#x25cf;</td>
                        <td style="line-height: 1.333;padding-left:8px">The add-on payment is available through an annual CMS process which identifies and ensures adequate payment for qualifying medical services and technologies under the inpatient prospective payment systems (IPPS)</td>
                    </tr>
                </table>
                	</td>
                </tr>
<tr>
    <td style="padding-top:20px;">
            <strong style="font-family: Arial, HelveticaNeue, Helvetica, sans-serif;color:#faa21b;font-size:26px;padding-left:20px">
                BLINCYTO add-on payment for FY 2016:
            </strong>
    </td></tr>
                <tr><td>

                                     <table width="550" align="left" border="0" cellpadding="0" cellspacing="0" style="font-family: Arial, HelveticaNeue, Helvetica, sans-serif; background-color: #ffffff;margin-top:15px;font-size: 18px;color:#005678">  
                <tr>
                	<td style="padding-left:20px">
                        <table style="font-family: arial; font-size: 18px;color:#005678" border="0">
                            <tbody>
                                <tr>
                                    <td style="color:#faa21b; vertical-align: top">&#x25cf;</td>
                                    <td colspan="2" style="line-height: 1.333;">CMS will pay either 50 percent of the cost of the new technology or 50 percent of the difference between the case cost and the DRG payment, with a maximum NTAP of $27,017.85</td>
                                </tr>
                                <tr>
                                    <td></td>
                                    <td style="color:#faa21b; vertical-align: top">&omicron;</td>
                                    <td>CMS will calculate add-on payment on a case-by-case basis using cost of case and actual DRG payment amounts<sup>*</sup></td>
                                </tr>
                                <tr>
                                    <td></td>
                                    <td style="color:#faa21b; vertical-align: top">&omicron;</td>
                                    <td>Hospital customers must utilize one of two unique ICD-10-PCSICD-10-PCS codes on claims to facilitate NTAP.</td>
                                </tr>
                            </tbody>
                        </table>
                    </td>
                                         </tr>
                                         <tr><td style="padding-left:20px">
                        <table style="border:1px solid #005678;margin-top:7px" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="background:#005677;color:#ffffff;font-weight:bold;font-size:16px;width:105px;text-align:center;padding:10px;margin:0">
                                    XW03351
                                </td>
                                <td style="color:#000000;font-weight:normal;font-size:12px;text-align:center;padding:0;margin:0">
                                    Introduction of Blinatumomab antineoplastic immunotherapy into <u>peripheral vein</u>, percutaneous approach, new technology group 1
                                </td>
                            </tr>
                        </table>
                                             </td>
                                         </tr>
                                         <tr><td style="padding-left:20px">
                        <table style="border:1px solid #005678;margin-top:7px;margin-bottom:20px" cellspacing="0" cellpadding="0">
                            <tr>
                                <td style="background:#005677;color:#ffffff;font-weight:bold;font-size:16px;width:105px;text-align:center;padding:10px;margin:0">
                                    XW04351
                                </td>
                                <td style="color:#000000;font-weight:normal;font-size:12px;text-align:center;padding:0;margin:0">
                                    Introduction of Blinatumomab antineoplastic immunotherapy into <u>peripheral vein</u>, percutaneous approach, new technology group 1
                                </td>
                            </tr>
                        </table>
                                             </td></tr>
                                         <tr>
                                             <td width="300" style="text-align: center;background:#ffffff;padding: 30px auto; color:#fff;font-weight: bold;font-size: 22px;padding-top:15px;padding-bottom:30px">
                                                 <table  cellspacing="0" cellpadding="0" bgcolor="#ffffff" align="center" style="margin:10px auto 0;border-collapse:collapse" >
                        
                        <tr><td align="center" style="font-family: arial; padding:15px 90px;padding-bottom:15px;background: #faa21b"> <a href="#" target="_blank" style="font-size:22px;color:#ffffff;text-decoration:none;vertical-align:middle;"><strong>Download the NTAP for <br>BLINCYTO<sup>&reg;</sup> brochure  &gt; </strong></a></td></tr>
                    </table>
                        </td>
                                             </tr>
            </table>
        </td>
</tr>
        </table>
    </td>
</tr>
